



an Open Access Journal by MDPI

## Advances in Cancer and Virus-Host Cell Interactions

Guest Editors:

### Dr. Mubashir Javed Minto

Department of Cell and  
Molecular Pharmacology and  
Experimental Therapeutics,  
Medical University of South  
Carolina, 171 Ashley Avenue,  
Charleston, SC 29425, USA

### Dr. Rakesh Sathish Nair

Department of Cell and  
Molecular Pharmacology,  
Medical University of South  
Carolina, 171 Ashley Avenue,  
Charleston, SC 29425, USA

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editors

The aim of this Special Issue is to provide a comprehensive and updated overview of the current knowledge and challenges in the field of cancer and virus–host cell interactions.

We welcome contributions from researchers working on different types of viruses that are linked to human cancers, such as human papillomaviruses (HPVs), hepatitis viruses B and C (HBV and HCV), human gammaherpesviruses (HHV4/Epstein–Barr Virus (EBV) and HHV8/Kaposi's Sarcoma-Associated Herpesvirus (KSHV), Merkel cell polyomavirus (MCPyV), and human T-cell leukemia virus I (HTLV-1). We also encourage submissions that explore the interactions between viruses and other factors that influence cancer development, such as genetics, epigenetics, immunity, metabolism, microbiome, etc.

The scope of this Special Issue is to provide a platform for researchers to share their latest findings and insights on the complex interplay between cancer and virus–host cell interactions. We hope that this Special Issue will stimulate further research and collaboration in this important and rapidly evolving field of biomedicine.



[mdpi.com/si/181849](https://mdpi.com/si/181849)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI